CoChat

The ‘united airways’ require an holistic approach to management

Cruz, Á. A. · 2005 · Allergy
Cited by 42

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

We live an era of fragmentation of knowledge in the context of an extraordinary analysis of nature. This has lead to an understanding of biological phenomena down to the molecular level. Unfortunately, one does not see as much progress in the desirable synthesis of the knowledge generated. In a recent publication, Togias has declared the respiratory system a victim of fragmented medical science (1). It is surprising that it took so long for the concept that nose and bronchi are both parts of one whole airway (2), in terms of the pathophysiology of asthma and rhinitis, to be widely accepted. Furthermore, a straightforward benefit of this new paradigm is not yet established for the management of these extremely common chronic illnesses. We have learned the epidemiological association between asthma and rhinitis is far stronger than previously thought (3). Patients with asthma and allergic rhinitis have greater costs and morbidity than those with symptoms of asthma alone (4). On the other hand, asthmatics with symptoms of rhinitis have worse quality of life (5). Rhinitis and asthma share common genetic and environmental risk factors, but rhinitis is a remarkable risk factor for asthma regardless of atopy (6, 7). We know now that the immunopathology of asthma and rhinitis is virtually the same and there is convincing imaging and histopathological evidence that chronic rhinitis is closely related to chronic sinusitis, and both of them are related to asthma (8–12). We have nowadays various options of intervention available, which may control symptoms of rhinosinusitis as well as those of asthma. Nevertheless, the practical consequences of the understanding that rhinitis, sinusitis and asthma are not different diseases, in general, but different manifestations of one only syndrome affecting the entire airway, seems to be far from satisfactory. This is true for the diagnostic approach as much as for the treatment. Several studies, performed among patients with allergic rhinitis and asthma, have demonstrated some degree of improvement or protection against asthma manifestations by the use of nasal corticosteroids, either in small clinical trials (13, 14) or in retrospective analysis of databases (15–17). However, a systematic review on the matter published recently did not demonstrate indisputable benefits from the intervention in question (18). Therefore, we should not be very surprised with the negative results published in this issue of Allergy by Dahl et al. (19). Their paper present a double-blind placebo-controlled study of 262 patients divided into four groups, to evaluate the effects of a nasal corticosteroid in protecting subjects with seasonal rhinitis and asthma from developing asthma symptoms. Their conclusion is that, in such patients, the combination of intranasal and inhaled corticosteroids is needed to control the seasonal increase in symptoms from the upper and lower airways. Why did three large database studies (15–17) find a marked reduction of asthma morbidity associated with rhinitis treatment? The three large retrospective studies were performed in the USA and demonstrated reduction in emergency visits and admissions among asthmatic subjects treated for their rhinitis, when compared with asthmatics not taking any rhinitis medication. We should remember that Dahl et al.'s trial meets the criteria for the best level of evidence: double-blind placebo-controlled randomized study with enough power, whereas all three studies demonstrating morbidity reduction are less reliable evidence because they were retrospective, and therefore more likely to be biased. For instance, patients suffering from asthma and rhinitis might have search medical assistance for dyspnoea related to nasal obstruction, which is not easily differentiated from dyspnoea of bronchial origin. Obviously, patients without treatment for rhinitis would more likely be at risk for this misclassification, when lack of control of rhinitis could be taken as lack of control of asthma, leading to emergency visits or even admissions. It is noteworthy calling attention to a recent publication by Sazonov Kocevar et al. (20) that demonstrates a striking higher risk of recurrent admissions in children with asthma and rhinitis, when compared to those with asthma and no diagnosis of rhinitis, in a broad population database in Norway. The negative results reported by Dahl et al. (19) should not be taken as definitive, however. Studies of efficacy of topical corticosteroids in allergic rhinitis do not demonstrate control of symptoms in 100% of subjects (21). Therefore, there is a case for subgroup post hoc analysis to be performed, in which only those subjects with nasal symptoms significant improvement would be considered for the benefit of the nasal corticosteroids in controlling asthma. A different conclusion might be reached. The absence of clear protection against seasonal asthma by use of nasal corticosteroids, in subjects with concomitant rhinit

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1398-9995.2005.00858.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 42

Metadata

Authors
Cruz, Á. A.
Venue
Allergy
Publisher
Wiley
Published
2005-06-02
Volume
60
Issue
7
Pages
871-874
ISSN
  • 0105-4538 (ISSN-L)
  • 1398-9995
OpenAlex
W2012295026
Cited by
42
References
12
FWCI
3.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The ‘united airways’ require an holistic approach to management. https://app.cochat.ai/papers/10.1111/j.1398-9995.2005.00858.x
The paper
Cruz, Á. A. (2005). The ‘united airways’ require an holistic approach to management. Allergy. https://doi.org/10.1111/j.1398-9995.2005.00858.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.